Histology Evaluation of Radiofrequency Ablation

April 21, 2023 updated by: Ochsner Health System

Histologic Evaluation Comparing Power Settings in Radiofrequency Ablation on Eyelash Follicles

Trichiasis is a disorder of misdirected eyelashes in which the lashes grow inward towards the eye. Trichiasis can occur as a result of chronic inflammation, infection, such as in herpes or trachoma, trauma, or rare diseases like ocular cicatricial pemphigoid or Stevens-Johnson syndrome. Trichiasis can result significant pain and corneal compromise, ranging from punctate erosions to frank abrasions, as the lashes constantly contact and irritate the ocular surface. Several treatment modalities are available, including mechanical epilation, electroepilation, cryotherapy, laser therapy, and surgical procedures to redirect the lashes. Radiofrequency ablation is a type of electroepilation that utilizes radiowaves to heat and destroy hair follicles. A fine needle is inserted into the follicle and current is applied to destroy the follicle. The needle allows the energy to be focused into the follicle and limits scarring of the surrounding tissues, and the follicles are in theory permanently destroyed in this procedure. Success rates are variable however, ranging from 56 to 90%. Currently, there is no standardized protocol for performing radiofrequency ablation. Many practitioners choose their power settings based on experience, and the Ellman Surgitron machine, a commonly used radiofrequency unit, actually states in their instructions that the power should be titrated based on user experience. In the literature, settings anywhere from 1 to 3 are seen. In this study, our purpose is to examine the effects of different power settings in radiofrequency at the histologic level. The investigators plan to test different power settings on eyelid tissue that would be normally excised and discarded during eyelid correction surgeries. The investigators hope to determine if there is an ideal power setting to achieve hair follicle destruction while minimizing surrounding tissue damage, which could then be used as the standard power setting for radiofrequency ablation of trichiatic lashes in clinical practice. The investigators hypothesize that as power increases, the extent and severity of tissue damage will increase.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Detailed Description

Subject fulfilling the inclusion and exclusion criteria and willing to participate in the study will be enrolled. All participants will receive all 4 treatments at the varying power settings (low, 1, 1.5, 2).

The patients will be prepped for their surgery in the usual fashion. This portion of the procedure is not experimental and is an elective surgery that the patients are choosing to undergo prior to enrolling in the study. This procedure is performed in the operating room. After adequate anesthesia is achieved, subcutaneous 2% lidocaine with epinephrine with 0.5% marcaine, and vitrase is injected into the lower eyelids and lateral canthal areas. The face is prepped and draped in sterile fashion using topical Betadine. A corneal shield will be placed into the fornix at this time. A lateral canthal incision is then made using a #15 blade. Straight Stevens scissors are used to perform a canthotomy and monopolar cautery was used to incise the inferior crus of the lateral canthal tendon. Hemostasis is maintained. The freed lower eyelid is draped over the zygoma. The excess eyelid is then excised full-thickness with Westcott scissors. (If this excess eyelid skin is at least 5 mm on both sides, the study will be performed and the treatments will be applied at this point). The tissue will be marked and divided into 4 equal sections (2 sections on each lid). Each section will be treated with the designated power setting in the following manner.

The probe will be inserted into the follicle under direct visualization to a depth of approximately 1.4 mm. The designated power will be applied for 1 second. All lashes in each segment will be treated. The segments will then be excised and placed into labelled and coded containers of formalin.

Attention will then be directed back to completing the lateral tarsal strip/eyelid surgery. The remainder of the surgery will be performed in the usual fashion and is not part of the experimental portion of the study. One 4-0 Vicryl on P-2 needle is then passed through the tarsus backhanded anterior inferiorly exiting posterior superiorly within the wound and then passed back through the periosteum approximately 3 mm from the orbital rim at the level of the superior crus of the lateral canthal tendon and temporarily tied. This procedure is repeated in full on the other side. The sides are compared. Once the proper contour and tightness is achieved, the suture is permanently tied in a horizontal mattress fashion after passing back through the remnants of the inferior crus. Attention is then turned to the upper lid, whose lateral mucocutaneous junction is trimmed using Westcott scissors. The gray lines of the lateral upper and lower eyelids arre reapposed using 6-0 Vicryl. The lateral canthal incisions are closed with a running 6-0 Prolene suture. Tobradex ointment is applied to the eye and eyelid. The patient is awakened and extubated and taken to the recovery room in stable condition. The patients will be examined at their post-operative week 1 and month 1 visits as per the usual standard of care. After the 1 month visit, their participation in the study is complete.

The tissue sections will be sent to the pathology department for sectioning and staining. The tissue will be sectioned through the follicles. The slides will be stained with hemotoxylin and eosin and Masson-Trichrome. The extent of tissue damage will be measured as the diameter of abnormal/damaged tissue in microns. The severity will be graded on a numerical scale from 0-3. The results will be compared among the 4 power settings.

Study Type

Interventional

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Undergoing the bilateral tarsal strip procedure
  • The procedure requires at least 5 mm of tissue to be excised from each side to provide adequate tightening of the lower eyelids (to be determined intra-operatively)
  • Caucasian (to control for any different responses ellicited by the treatment in pigmented skin)

Exclusion Criteria:

  • previous treatments for trichiasis along the lateral lower eyelid
  • madarosis of eyelashes
  • hypertrichosis of eyelashes
  • patients undergoing only unilateral tarsal strip procedures
  • history of eyelid trauma or chemical burns
  • patients with a history of disorders affecting the mucus membranes (ie: Stevens-Johnson syndrome, ocular cicatricial pemphigoid)
  • history of eyelid surgery
  • history of facial skin cancers
  • patients with eyelid lesions affecting the lateral lower eyelids
  • patients with active inflammatory ocular diseases (keratitis, scleritis, conjunctivitis, etc).

These exclusion criteria are to generally encompass and exclude any eyelid or eyelash pathology that may confuse what histology changes are from the study treatments versus what pathology was already there at baseline.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Non-Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Low power
These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of "low."
The eyelid segments to be excised as part of their planned lateral tarsal strip procedure will be marked and divided into 4 equal sections (2 sections on each lid). A corneal shield will be placed into the fornix prior to treatment. Each section will be treated with the designated power setting in the following manner. The probe will be inserted into the follicle under direct visualization to a depth of approximately 1.4 mm. The designated power will be applied for 1 second. All lashes in each segment will be treated. The segments will then be excised and placed into labelled and coded containers of formalin.
Experimental: 1 power
These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 1.
The eyelid segments to be excised as part of their planned lateral tarsal strip procedure will be marked and divided into 4 equal sections (2 sections on each lid). A corneal shield will be placed into the fornix prior to treatment. Each section will be treated with the designated power setting in the following manner. The probe will be inserted into the follicle under direct visualization to a depth of approximately 1.4 mm. The designated power will be applied for 1 second. All lashes in each segment will be treated. The segments will then be excised and placed into labelled and coded containers of formalin.
Experimental: 1.5 power
These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 1.5
The eyelid segments to be excised as part of their planned lateral tarsal strip procedure will be marked and divided into 4 equal sections (2 sections on each lid). A corneal shield will be placed into the fornix prior to treatment. Each section will be treated with the designated power setting in the following manner. The probe will be inserted into the follicle under direct visualization to a depth of approximately 1.4 mm. The designated power will be applied for 1 second. All lashes in each segment will be treated. The segments will then be excised and placed into labelled and coded containers of formalin.
Experimental: 2 power
These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 2.
The eyelid segments to be excised as part of their planned lateral tarsal strip procedure will be marked and divided into 4 equal sections (2 sections on each lid). A corneal shield will be placed into the fornix prior to treatment. Each section will be treated with the designated power setting in the following manner. The probe will be inserted into the follicle under direct visualization to a depth of approximately 1.4 mm. The designated power will be applied for 1 second. All lashes in each segment will be treated. The segments will then be excised and placed into labelled and coded containers of formalin.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Extent of tissue damage
Time Frame: Through study completion, approximately 6 months
The extent of damage will be measured on the tissue sections. The diameter of abnormal/damaged tissue will be measured in microns.
Through study completion, approximately 6 months
Severity of tissue damage
Time Frame: Through study completion, approximately 6 months
The severity will be graded on a scale from 0 to 3, with 0 being no tissue changes and going up to 3 which will represent severe tissue changes.
Through study completion, approximately 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Priya Sahu, MD, Ochsner Health System
  • Principal Investigator: Jayne Weiss, MD, Louisiana State University Health Sciences Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 2, 2019

Primary Completion (Actual)

June 22, 2020

Study Completion (Actual)

June 22, 2020

Study Registration Dates

First Submitted

May 7, 2019

First Submitted That Met QC Criteria

May 10, 2019

First Posted (Actual)

May 13, 2019

Study Record Updates

Last Update Posted (Actual)

April 25, 2023

Last Update Submitted That Met QC Criteria

April 21, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • STUDY00000551
  • LSU IRB (Other Identifier: 19-016)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

No plan to share with other researchers

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Trichiasis

Clinical Trials on Radiofrequency ablation

Subscribe